Announcement • May 03
Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million. Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,333,334
Price\Range: $3
Discount Per Security: $0.21 New Risk • Feb 26
New major risk - Revenue and earnings growth Earnings have declined by 5.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$20.7m market cap). Announcement • Feb 04
Regentis Biomaterials Ltd. Announces the Appointment of Ori Gon as Chief Financial Officer, Effective February 4, 2026 Regentis Biomaterials Ltd. announced the appointment of Ori Gon as Chief Financial Officer, effective February 4, 2026. Mr. Gon will lead the Company's commercial and business development activities, as well as its financial strategy, planning, and reporting. Mr. Gon joins Regentis at a pivotal time as GelrinC®, the Company's proprietary hydrogel implant for knee cartilage repair, advances towards commercial launch in Europe following CE Mark approval and is being evaluated in a pivotal Phase III FDA clinical trial in the United States. Mr. Gon brings over 15 years of financial leadership experience across public and private enterprises and medical technology. Most recently, he served as CFO at Tactile Mobility, a sensing and data analytics company focused on advanced automotive and mobility applications. Prior to that, he held senior financial leadership roles at ReWalk Robotics Inc., now Nasdaq-listed Lifeward Ltd., a pioneer in wearable robotic exoskeletons for individuals with lower limb disabilities, where he served as CFO and Corporate Controller. Earlier in his career, he was Controller at On Track Innovations Ltd., a Nasdaq- and Neuer Markt-listed fintech company. He began his professional career as an auditor at KPMG Israel. Mr. Gon has led multiple secondary public offerings and financing transactions across various structures, raising over $150 million in aggregate capital. He is a Certified Public Accountant (CPA) in Israel. 
